REGENXBIO Inc. Stock News

REGENXBIO is doing important R&D for gene therapies for the eye. The stock is down due to a lack of near-term catalysts and little revenue.

REGENXBIO Inc. (NASDAQ:RGNX ) Q3 2022 Earnings Conference Call November 3, 2022 8:30 AM ET Company Participants Patrick Christmas - Chief Legal Officer Vit Vasista - Chief Financial Officer Ken Mills

ROCKVILLE, Md. , Nov. 2, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following upcoming investor conferences: Credit Suisse 31st Annual Healthcare Co

ROCKVILLE, Md. , Oct. 27, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present data from the ALTITUDE® clinical trial evaluating RGX-314 using suprachoroidal deliv

A company with a market value of about $1 billion is small enough to grow fast, yet large enough so that it can begin to appeal to institutional investors such as pension funds.

Due to its tremendous pressure, the 2021/2022 Biotech Bear market knocked out nearly all biotech innovators. Nevertheless, certain rare companies like Regenxbio are defying bear market expectations.

ROCKVILLE, Md. , Sept. 6, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following upcoming investor conferences: Morgan Stanley 20th Annual Global Heal

ROCKVILLE, Md. , Aug. 10, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present at the H.C.

REGENXBIO Inc. (NASDAQ:RGNX ) Q2 2022 Earnings Conference Call August 3, 2022 4:30 PM ET Company Participants Vit Vasista - Chief Financial Officer Ken Mills - President & Chief Executive Officer Stev

Regenxbio (RGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ROCKVILLE, Md. , Aug. 1, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Wednesday, August 3, 2022, at 4:30 p.m.

RGNX is proceeding towards becoming a pillar of the gene therapy space for ocular diseases. However, it will need time to get there.

The S&P 500 is one of the most popular U.S. stock indices and is often what investors and experts are referring to when they mention the "stock market." However, there's more to the market than large-

REGENXBIO Inc. (NASDAQ:RGNX ) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Patrick Christmas - Chief Legal Officer Ken Mills - President and CEO Steve Pakola - Chief Me

ROCKVILLE, Md. , May 4, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following upcoming investor conferences: Bank of America Securities 2022 Healthcar